Zacks Investment Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$177M Buy
815,533
+133,200
+20% +$29.5M 1.42% 15
2025
Q4
$156M Sell
682,333
-105,441
-13% -$24M 1.22% 17
2025
Q3
$182M Sell
787,774
-32,025
-4% -$6.52M 1.45% 13
2025
Q2
$152M Buy
819,799
+4,746
+0.6% +$882K 1.3% 15
2025
Q1
$171M Buy
815,053
+58,192
+8% +$11.3M 1.59% 12
2024
Q4
$134M Sell
756,861
-96,346
-11% -$17.7M 1.25% 16
2024
Q3
$168M Buy
853,207
+84,395
+11% +$15.8M 1.46% 13
2024
Q2
$132M Buy
768,812
+45,526
+6% +$7.54M 1.48% 15
2024
Q1
$132M Buy
723,286
+86,000
+13% +$14.8M 1.4% 14
2023
Q4
$98.8M Sell
637,286
-44,228
-6% -$6.45M 1.22% 19
2023
Q3
$102M Buy
681,514
+1,651
+0.2% +$242K 1.32% 18
2023
Q2
$91.6M Buy
679,863
+8,081
+1% +$1.19M 1.15% 21
2023
Q1
$107M Buy
671,782
+19,647
+3% +$3M 1.43% 15
2022
Q4
$105M Buy
652,135
+28,952
+5% +$4.44M 1.47% 16
2022
Q3
$83.6M Sell
623,183
-37,266
-6% -$5.35M 1.34% 15
2022
Q2
$101M Buy
660,449
+36,715
+6% +$5.61M 1.54% 12
2022
Q1
$101M Buy
623,734
+24,438
+4% +$3.55M 1.4% 14
2021
Q4
$81.1M Buy
599,296
+45,257
+8% +$5.35M 1.14% 21
2021
Q3
$59.8M Buy
554,039
+22,781
+4% +$2.6M 0.94% 29
2021
Q2
$59.8M Buy
531,258
+11,757
+2% +$1.32M 0.97% 30
2021
Q1
$56.2M Sell
519,501
-15,682
-3% -$1.68M 1% 25
2020
Q4
$57.3M Sell
535,183
-26,131
-5% -$2.51M 1.06% 21
2020
Q3
$49.2M Sell
561,314
-21,527
-4% -$2.03M 1% 30
2020
Q2
$57.2M Buy
582,841
+118,031
+25% +$10.4M 1.26% 20
2020
Q1
$35.4M Buy
464,810
+18,537
+4% +$1.58M 0.87% 42
2019
Q4
$39.5M Buy
446,273
+3,594
+0.8% +$298K 0.74% 48
2019
Q3
$33.5M Buy
442,679
+10,440
+2% +$716K 0.67% 49
2019
Q2
$31.4M Buy
432,239
+20,378
+5% +$1.6M 0.64% 51
2019
Q1
$33.2M Sell
411,861
-4,351
-1% -$356K 0.71% 48
2018
Q4
$38.4M Sell
416,212
-7,140
-2% -$628K 0.93% 33
2018
Q3
$40M Sell
423,352
-1,170
-0.3% -$111K 0.84% 39
2018
Q2
$39.3M Buy
424,522
+4,929
+1% +$481K 0.86% 35
2018
Q1
$39.7M Sell
419,593
-166,381
-28% -$18.3M 0.88% 34
2017
Q4
$56.7M Buy
585,974
+7,282
+1% +$686K 1.24% 21
2017
Q3
$51.4M Buy
578,692
+3,944
+0.7% +$300K 1.2% 22
2017
Q2
$41.7M Buy
574,748
+9,771
+2% +$657K 1.03% 28
2017
Q1
$36.8M Buy
564,977
+37,745
+7% +$2.37M 0.94% 31
2016
Q4
$33M Buy
527,232
+14,076
+3% +$859K 0.95% 29
2016
Q3
$32.4M Buy
513,156
+43,845
+9% +$2.84M 0.92% 31
2016
Q2
$29.1M Buy
469,311
+12,608
+3% +$768K 0.89% 29
2016
Q1
$26.1M Buy
456,703
+19,056
+4% +$1.06M 0.83% 32
2015
Q4
$25.9M Sell
437,647
-11,192
-2% -$645K 0.85% 36
2015
Q3
$24.4M Sell
448,839
-12,859
-3% -$837K 0.85% 35
2015
Q2
$31M Sell
461,698
-48,595
-10% -$3.17M 0.98% 26
2015
Q1
$29.9M Buy
510,293
+20,625
+4% +$1.25M 0.95% 28
2014
Q4
$32M Buy
489,668
+27,822
+6% +$1.75M 1.04% 26
2014
Q3
$26.6M Buy
461,846
+29,687
+7% +$1.65M 0.93% 28
2014
Q2
$24.4M Buy
432,159
+20,290
+5% +$1.06M 0.87% 30
2014
Q1
$21.2M Buy
411,869
+30,086
+8% +$1.52M 0.78% 32
2013
Q4
$20.2M Buy
381,783
+223,176
+141% +$11M 0.8% 28
2013
Q3
$7.09M Buy
158,607
+15,985
+11% +$709K 0.31% 123
2013
Q2
$5.9M Buy
+142,622
New +$6.24M 0.27% 131

Other funds holding ABBV

Zacks Investment Management's ABBV Position: Q1 2026 in Review

Zacks Investment Management increased its AbbVie (ABBV) stake by 20% in Q1 2026, buying an estimated $29.5M and bringing the position to 815,533 shares worth $177M. The position accounts for 1.42% of the portfolio, ranked #15.

Zacks Investment Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $182M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Zacks Investment Management held 815,533 shares of AbbVie worth $177M as of Q1 2026.
  • Zacks Investment Management bought 133,200 AbbVie shares in Q1 2026, an estimated $29.5M.
  • AbbVie made up 1.42% of Zacks Investment Management's portfolio in Q1 2026, its #15 holding.
  • Zacks Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Zacks Investment Management's AbbVie position peaked at $182M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.